Rositsa Koleva-Kolarova
PhD
Senior Researcher
Rositsa joined HERC in May 2019 as a senior researcher. Currently she works on a Horizon2020 funded project called HEcoPerMed (Health Economics for Personalised Medicine), which aims to provide guidance on state-of-the-art health economic modelling, and on financing and payment strategies for personalised medicine, to distinguish promises from reality.
Previously she held an appointment as a research fellow in health economics in the Department of Population Health Sciences, School of Population Health & Environmental Sciences, King’s College London. She worked on economic evaluation projects on stratifying antihypertensive treatment according to individuals’ ethnicity background, pharmacogenetics and pharmacogenomics for cardiovascular diseases, and evaluating new models of care (Vanguards).
Rositsa obtained her PhD from the University of Groningen, the Netherlands, and held an appointment as an assistant professor at the Department of Public Health Sciences, Faculty of Public Health, Medical University Pleven, Bulgaria.
Recent publications
-
Genetic-Guided Pharmacotherapy for Coronary Artery Disease: A Systematic and Critical Review of Economic Evaluations.
Lim KK. et al, (2024), J Am Heart Assoc
-
Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.
Kovács G. et al, (2023), Per Med
-
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies.
Nagy B. et al, (2023), Per Med
-
Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
Koleva-Kolarova R. et al, (2023), Per Med
-
Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries
Szilberhorn L. et al, (2023), Personalized Medicine